Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

SNOA


Top 10 Correlated ETFs

SNOA


Top 10 Correlated Stocks

SNOA


In the News

01:13 25 Sep 2022 SNOA

Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today?

Sonoma Pharmaceuticals (SNOA) stock is getting a boost on Tuesday after the company revealed positive disinfectant news from the EPA. The post Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today?

09:33 25 Sep 2022 SNOA

Best Penny Stocks to Buy Today? 3 to Watch on May 3rd

What to know about buying penny stocks on May 3rd The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

01:41 25 Sep 2022 SNOA

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

11:27 25 Sep 2022 SNOA

Sonoma Pharma Launches New Urinary Tract Infection Product In New Zealand, Australia, South Africa

Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has launched Microdox, an urinary tract infection catheter and bladder rinse in New Zealand, Australia, and South Africa. Microdox is a super-oxidized solution based on Sonoma's patented Microcyn Technology intended to treat and prevent.

04:55 25 Sep 2022 SNOA

Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference. The conference is being held on January 10-13, 2022 virtually. Amy Trombly, CEO and Jerry Dvon

07:28 25 Sep 2022 SNOA

SNOA Stock: Why The Price Increased Substantially Today

The stock price of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) increased by over 20% pre-market today. This is why it happened.

07:00 25 Sep 2022 SNOA

Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time

WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group, announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer, which is ma

01:29 25 Sep 2022 SNOA

7 Popular Penny Stocks That You Shouldn't Touch With a 10-Foot Pole

Penny stocks can be risky investments. These seven popular penny stocks seem like particularly bad bets no matter how you look at it.

08:31 25 Sep 2022 SNOA

SNOA Stock: Why It Substantially Increased Today

The stock price of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) increased by over 65% pre-market today. This is why it happened.

08:03 25 Sep 2022 SNOA

Why Are Sonoma Pharma Shares Rallying Today?

Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) has announced the OTC consumer launch of Regenacyn Advanced Scar Gel and Ocucyn Eyelid & Eyelash Cleanser on Amazon.com and MucoClyns on Amazon sites in Europe.  All three products are based on Sonoma's Microcyn technology and are immediately available for customer orders.

Financial details

Company Rating
Buy
Market Cap
9.15M
Income
-4.88M
Revenue
12.93M
Book val./share
2.57
Cash/share
1.8
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
14 Nov 2022
P/E
-1.39
Forward P/E
-
PEG
1.24
P/S
0.52
P/B
0.85
P/C
1.21
P/FCF
-1.45
Quick Ratio
1.65
Current Ratio
3.05
Debt / Equity
0.03
LT Debt / Equity
0.03
-
-
EPS (TTM)
-1.75
EPS next Y
-
EPS next Q
-
EPS this Y
-2.54%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-41.67%
Revenue last 5Y
-5.39%
Revenue Q/Q
73.32%
EPS Q/Q
-73.87%
-
-
-
-
SMA20
-9.63%
SMA50
-7.17%
SMA100
-3.2%
Inst Own
100%
Inst Trans
0%
ROA
-28%
ROE
-50%
ROC
-0.47%
Gross Margin
31%
Oper. Margin
-45%
Profit Margin
-38%
Payout
-
Shs Outstand
3.1M
Shs Float
3.08M
-
-
-
-
Target Price
-
52W Range
2.55-8.76
52W High
-72.75%
52W Low
+9%
RSI
23.08
Rel Volume
0.4
Avg Volume
51.94K
Volume
20.64K
Perf Week
-24.31%
Perf Month
-34.14%
Perf Quarter
-40.6%
Perf Half Y
-31.45%
-
-
-
-
Beta
0.950459
-
-
Volatility
0.26%, 0.21%
Prev Close
-13.15%
Price
2.18
Change
-16.15%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-03-31

Metric History 2018-03-312019-03-312020-03-312021-03-31 2022-03-31
Revenue per share
33.120.5312.829.334.76
Net income per share
-28.47-12.77-1.99-1.98-1.92
Operating cash flow per share
-24.71-12.68-3.11-1.69-1.6
Free cash flow per share
-25.08-12.79-3.25-1.78-1.65
Cash per share
203.992.52.112.79
Book value per share
30.4511.355.892.693.28
Tangible book value per share
30.4511.355.892.693.28
Share holders equity per share
30.4511.355.892.693.28
Interest debt per share
0.60.40.341.350.51
Market cap
17.17M7.32M7.5M15.47M7.06M
Enterprise value
7.36M3.96M4.29M13.92M1.03M
P/E ratio
-1.2-0.62-2.55-3.92-1.39
Price to sales ratio
1.030.390.40.830.56
POCF ratio
-1.38-0.62-1.63-4.58-1.66
PFCF ratio
-1.36-0.62-1.56-4.35-1.61
P/B Ratio
1.120.70.862.880.81
PTB ratio
1.120.70.862.880.81
EV to sales
0.440.210.230.750.08
Enterprise value over EBITDA
-0.53-0.37-1.72-4.64-0.2
EV to operating cash flow
-0.59-0.34-0.94-4.12-0.24
EV to free cash flow
-0.58-0.34-0.89-3.91-0.23
Earnings yield
-0.83-1.61-0.39-0.26-0.72
Free cash flow yield
-0.74-1.61-0.64-0.23-0.62
Debt to equity
0000.340.04
Debt to assets
0.20.270.40.640.54
Net debt to EBITDA
0.710.311.290.521.15
Current ratio
4.983.482.553.182.82
Interest coverage
-354.73-341.15-416.94-287.42588.7
Income quality
0.870.991.560.860.84
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.20.980.7200
Research and developement to revenue
0.090.080.070.030.01
Intangibles to total assets
00000
Capex to operating cash flow
0.020.010.040.050.03
Capex to revenue
-0.01-0.01-0.01-0.01-0.01
Capex to depreciation
-0.38-0.22-0.66-0.79-0.74
Stock based compensation to revenue
0.140.090.040.020.03
Graham number
139.6557.1116.2610.9411.89
ROIC
-0.89-1.04-0.69-0.32-0.45
Return on tangible assets
-0.75-0.82-0.2-0.26-0.27
Graham Net
17.435.162-0.320.82
Working capital
12.99M8.91M7.52M8.91M10.61M
Tangible asset value
00000
Net current asset value
12.37M8.54M6.53M3.36M6.28M
Invested capital
0.020.030.060.50.16
Average receivables
3.1M4.55M5.01M4.66M4.72M
Average payables
1.52M1.51M1.93M1.77M1.71M
Average inventory
2.7M2.97M2.36M2.53M2.6M
Days sales outstanding
33.6885.51103.4591.23138.1
Days payables outstanding
49.6745.471.8153.569.36
Days of inventory on hand
111.87123.3275.4676.51112.56
Receivables turnover
10.844.273.5342.64
Payables turnover
7.358.045.086.825.26
Inventory turnover
3.262.964.844.773.24
ROE
-0.93-1.12-0.34-0.74-0.58
Capex per share
-0.37-0.11-0.14-0.09-0.05

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q1

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
1.761.60.940.871.28
Net income per share
-0.52-0.04-0.31-1.11-0.29
Operating cash flow per share
-0.58-0.56-0.11-0.53-0.49
Free cash flow per share
-0.61-0.57-0.11-0.55-0.5
Cash per share
1.343.582.772.791.8
Book value per share
2.214.893.633.282.57
Tangible book value per share
2.214.893.633.282.57
Share holders equity per share
2.214.893.633.282.57
Interest debt per share
1.160.630.390.510.31
Market cap
15.36M13.08M14.04M10.64M9.05M
Enterprise value
14.98M6.17M6.73M4.61M4.42M
P/E ratio
-3.5-32.7-3.72-0.9-2.55
Price to sales ratio
4.173.494.844.632.27
POCF ratio
-12.56-10.03-43.08-7.63-5.91
PFCF ratio
-12.08-9.84-42.95-7.3-5.82
P/B Ratio
3.321.141.261.221.14
PTB ratio
3.321.141.261.221.14
EV to sales
4.071.652.322.011.11
Enterprise value over EBITDA
-14.27-143.57-7.44-1.42-4.96
EV to operating cash flow
-12.25-4.73-20.63-3.3-2.88
EV to free cash flow
-11.78-4.65-20.57-3.16-2.84
Earnings yield
-0.07-0.01-0.07-0.28-0.1
Free cash flow yield
-0.08-0.1-0.02-0.14-0.17
Debt to equity
0.10.040.030.040.03
Debt to assets
0.670.420.420.540.54
Net debt to EBITDA
0.36160.68.11.865.2
Current ratio
2.324.424.572.823.05
Interest coverage
00-319.333400
Income quality
1.1113.040.350.471.73
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.0200.0100
Intangibles to total assets
00000
Capex to operating cash flow
0.040.0200.040.02
Capex to revenue
-0.01-0.010-0.03-0.01
Capex to depreciation
-1.02-0.48-0.03-1.27-0.74
Stock based compensation to revenue
0.020.010.020.090.05
Graham number
5.12.1759.054.06
ROIC
-0.1-0.06-0.06-0.23-0.07
Return on tangible assets
-0.08-0.01-0.05-0.16-0.05
Graham Net
-1.51.631.280.82-0.13
Working capital
6.92M13.94M13.82M10.61M9.96M
Tangible asset value
00000
Net current asset value
2.66M9.65M9.52M6.28M5.62M
Invested capital
0.530.130.110.160.12
Average receivables
3.89M4.1M3.82M4.78M3.61M
Average payables
1.74M1.76M1.61M1.64M1.85M
Average inventory
2.64M2.57M2.77M2.66M2.73M
Days sales outstanding
73.2482.1288.51187.1355
Days payables outstanding
73.8667.4683.8667.0772.97
Days of inventory on hand
105.6989.24152.51108.8498.9
Receivables turnover
1.231.11.020.481.64
Payables turnover
1.221.331.071.341.23
Inventory turnover
0.851.010.590.830.91
ROE
-0.24-0.01-0.08-0.34-0.11
Capex per share
-0.02-0.010-0.02-0.01

Frequently Asked Questions

What is Sonoma Pharmaceuticals, Inc. stock symbol ?

Sonoma Pharmaceuticals, Inc. is a US stock , located in Woodstock of Georgia and trading under the symbol SNOA

What is Sonoma Pharmaceuticals, Inc. stock quote today ?

Sonoma Pharmaceuticals, Inc. stock price is $2.18 today.

Is Sonoma Pharmaceuticals, Inc. stock public?

Yes, Sonoma Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap